Who are Tozinameran 12 Years of age and older's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COVID-19 mRNA vaccine, Spikevax bivalent Original/Omicron BA.1, mRNA-1273 Variant-containing Formulation, Casirivimab and Imdevimab Drug Combination, batch 3 of Ad5-nCoV, COMIRNATY intramuscular injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tozinameran-12-years-of-age-and-older.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Tozinameran 12 Years of age and older — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tozinameran 12 Years of age and older (tozinameran-12-years-of-age-and-older) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine SARS-CoV-2 spike protein Immunology Live · refreshed every 30 min

Target snapshot

Tozinameran 12 Years of age and older (tozinameran-12-years-of-age-and-older) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tozinameran 12 Years of age and older TARGET	tozinameran-12-years-of-age-and-older	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tozinameran 12 Years of age and older — Competitive Intelligence Brief. https://druglandscape.com/ci/tozinameran-12-years-of-age-and-older. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab